Biocon Limited has informed the Exchange regarding a press release dated May 21, 2024, titled "Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili . Enters U.S. Ophthalmology Market".
Biocon Limited has informed the Exchange regarding a press release dated May 21, 2024, titled "Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili . Enters U.S. Ophthalmology Market".